Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6LQIU)

• Drug Name: VIR-2482 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Influenza A virus infection	1E30	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM6LQIU

Molecule-Related Drug Atlas

Drug(s) Targeting Influenza Hemagglutinin (Influ HA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arbidol	DMOQK8Z	Virus infection	1A24-1D9Z	Approved	[3]
CR8020	DMQ47U6	Influenza virus infection	1E30-1E32	Phase 2	[4]
RG7745	DMK5PYS	Infectious disease	1A00-CA43.1	Phase 2	[5]
VIS410	DM1G6ME	Influenza A virus infection	1E30	Phase 2	[6]
ND-1.1	DMVQAEK	Influenza virus infection	1E30-1E32	Phase 1	[7]
VGX-3400	DMGMEH7	Influenza A virus H5N1 infection	1E30	Phase 1	[8]
A/Anhui/05	DMGJ7A4	Influenza virus infection	1E30-1E32	Phase 1	[9]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[10]
BMY-27709	DMAMYWL	Discovery agent	N.A.	Investigative	[11]
PXVX-0103	DM2P0I4	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Influenza Hemagglutinin (Influ HA)	TTF4CAM	HEMA_I34A1	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04033406) Study of VIR-2482 in Healthy Volunteers. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Vir Biotechnology.
• [3] Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
• [4] Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
• [5] Clinical pipeline report, company report or official report of Roche.
• [6] Clinical pipeline report, company report or official report of Visterra.
• [7] An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
• [8] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [9] A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
• [12] Company report (PaxVax)